Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07739706

A Novel Smartphone Application for Helping Teens Stop Vaping, QuitQuest Vaping R01

This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Despite recent declines, data shows that 8.5% of middle school (grades 6-8) and 18.1% of high school (grades 9-12) students in the United States (US) used electronic nicotine delivery systems (ENDS; variously known as vaping, electronic [e]-cigarettes, e-cigs, mods, and tank systems that contain nicotine). Use of any tobacco product during adolescence increases risk for lifelong nicotine addiction. ENDS use, in particular, leads to severe asthma attacks, e-cigarette or vaping product use-associated lung injury (EVALI), exposure to multiple lung irritants, including volatile organic compounds, and lasting harm to adolescent brain development. Despite evidence of potential long-term harms from ENDS, to date there have been limited evidence-based therapeutic options for ENDS cessation for adolescents and young adults. Traditional methods for delivering adolescent ENDS cessation interventions (e.g., quitlines and clinics) have limited reach. QuitQuest utilizes Acceptance and Commitment Therapy (ACT), a psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility, reduce distress, and promote behavior change through mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. The SFTQV program is based on the US Clinical Practice Guidelines, offering practical advice and support via an app delivery format. The QuitQuest app may work better than the SFTQV app in increasing vape quit rates among teens.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

13 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

Location contact

Jonathan Bricker, PhD

CONTACT

[email protected]

206-667-5074

Jonathan Bricker, PhD

PRINCIPAL_INVESTIGATOR

About this study

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants download and install the QuitQuest app for 12 months on study.

ARM II: Participants utilize the National Cancer Institute's (NCI's) SFTQV app for 12 months on study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 13 to 17
  • Used ENDS at least weekly in the past 30 days
  • Wants to quit ENDS within the next 30 days
  • If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
  • Interest in learning skills to quit ENDS
  • Willing to be randomly assigned to either condition
  • Resides in the United States (US) for the next 12 months
  • Has daily access to their own smartphone
  • Ability to download a smartphone app
  • Able to read in English
  • Not using other ENDS cessation interventions
  • Have not participated in our prior studies
  • No household or family member participating
  • Willingness to complete survey and biochemical assessments at 3, 6, and 12 months
  • Providing phone number(s), email, and mailing address

Exclusion criteria

  • Exclusion criteria are the reverse of the inclusion criteria

Treatment and study plan

Smartphone Application-based Intervention

Behavioral

Use QuitQuest app

Other names: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention

Survey Administration

Other

Ancillary studies

interview

Other

Ancillary studies

Primary outcomes

  1. Self-reported 30-day point prevalence abstinence (PPA) from electronic nicotine delivery systems (ENDS) use

    Time frame: At 6 months post-randomization

    Biochemical verification will be used to validate self-reported abstinence among participants who opt in at baseline and complete testing. In the primary intent-to-treat analysis, participants with missing 6-month self-reported outcome data will be classified as vaping. The primary missing=vaping outcome is based on self-reported 30-day ENDS use status, not on completion of biochemical verification. Participants who self-report abstinence but do not complete biochemical testing will not be automatically classified as vaping solely because biochemical verification is missing. The primary logistic regression model will adjust for the stratification factors used in randomization to appropriately account for study design, thereby improving the estimation of standard errors and increasing the validity of significance tests for the main treatment effect.

Secondary outcomes

  1. Self-reported 30-day PPA from ENDS use

    Time frame: At 3 and 12 months post-randomization

    Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.

  2. Self-reported 24-hour PPA from ENDS use

    Time frame: At 3, 6, and 12 months post-randomization

    Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.

  3. Self-reported 7-day PPA from ENDS use

    Time frame: At 3, 6, and 12 months post-randomization

    Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.

  4. Self-reported 30-day PPA from ENDS use

    Time frame: At 3, 6, and 12 months post-randomization

    Will investigate repeated 30-day PPA across 3, 6, and 12 months using mixed effects modeling.

  5. Biochemical verification of self-reported abstinence among participants who opt in at baseline and complete testing

    Time frame: Up to 12 months post-randomization

Study contacts

Contact information is provided by the study sponsor or research team.

Jonathan Bricker, PhD

CONTACT

[email protected]

206-667-5074

Sponsors and collaborators

Lead sponsor

Fred Hutchinson Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

QuitQuest: Full Scale Randomized Trial of a Novel Smartphone Application to Help Teens Stop Vaping (QuitQuest Vaping R01)

Important dates

Study start
2026
Primary completion
2030
Study completion
2031
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.